AU742216B2 - Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis - Google Patents
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis Download PDFInfo
- Publication number
- AU742216B2 AU742216B2 AU95658/98A AU9565898A AU742216B2 AU 742216 B2 AU742216 B2 AU 742216B2 AU 95658/98 A AU95658/98 A AU 95658/98A AU 9565898 A AU9565898 A AU 9565898A AU 742216 B2 AU742216 B2 AU 742216B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- composition
- antigen
- mutated
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 79
- 238000000034 method Methods 0.000 title claims description 26
- 230000011132 hemopoiesis Effects 0.000 title claims description 12
- 230000012010 growth Effects 0.000 title claims description 10
- 230000001613 neoplastic effect Effects 0.000 title claims description 7
- 230000002195 synergetic effect Effects 0.000 title description 3
- 108091007433 antigens Proteins 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 71
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000009472 formulation Methods 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 35
- 230000001506 immunosuppresive effect Effects 0.000 claims description 29
- 230000004044 response Effects 0.000 claims description 23
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 239000003599 detergent Substances 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 230000002222 downregulating effect Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 9
- 230000003071 parasitic effect Effects 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 239000007764 o/w emulsion Substances 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229920002359 Tetronic® Polymers 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 102000001301 EGF receptor Human genes 0.000 claims description 5
- 108060006698 EGF receptor Proteins 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 241001631646 Papillomaviridae Species 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 4
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 108050006400 Cyclin Proteins 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 102100039554 Galectin-8 Human genes 0.000 claims description 4
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims description 4
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims description 4
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- 102000015728 Mucins Human genes 0.000 claims description 4
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 4
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 102000002938 Thrombospondin Human genes 0.000 claims description 4
- 108060008245 Thrombospondin Proteins 0.000 claims description 4
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229940051875 mucins Drugs 0.000 claims description 4
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 4
- KMXFZRSJMDYPPG-UHFFFAOYSA-N tetratetracontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC KMXFZRSJMDYPPG-UHFFFAOYSA-N 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 229920002046 Pluronic® L 62 LF Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 102000023732 binding proteins Human genes 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 4
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 3
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 claims 3
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims 3
- 238000012737 microarray-based gene expression Methods 0.000 claims 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 3
- YKNFBGRYAKVNNI-UHFFFAOYSA-N 2-[1-[2-[bis[2-(2-hydroxyethoxy)propyl]amino]ethyl-[2-(2-hydroxyethoxy)propyl]amino]propan-2-yloxy]ethanol Chemical compound OCCOC(C)CN(CC(C)OCCO)CCN(CC(C)OCCO)CC(C)OCCO YKNFBGRYAKVNNI-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 12
- 239000003636 conditioned culture medium Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000009618 Transforming Growth Factors Human genes 0.000 description 7
- 108010009583 Transforming Growth Factors Proteins 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- -1 TGF1R-1 Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 102000004145 Annexin A1 Human genes 0.000 description 2
- 108090000663 Annexin A1 Proteins 0.000 description 2
- 241000043587 Collimonas fungivorans Species 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 108010014723 immunosuppressive acidic protein Proteins 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102000039506 BAGE family Human genes 0.000 description 1
- 108091067183 BAGE family Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101710192036 Sporozoite surface protein 2 Proteins 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 101710084188 TGF-beta receptor type-2 Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 101710132313 Transforming growth factor beta receptor type 3 Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000023750 transforming growth factor beta production Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93335997A | 1997-09-18 | 1997-09-18 | |
| US08/933359 | 1997-09-18 | ||
| PCT/US1998/018495 WO1999013912A1 (en) | 1997-09-18 | 1998-09-17 | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU9565898A AU9565898A (en) | 1999-04-05 |
| AU742216B2 true AU742216B2 (en) | 2001-12-20 |
Family
ID=25463798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU95658/98A Ceased AU742216B2 (en) | 1997-09-18 | 1998-09-17 | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
Country Status (18)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| JP4751556B2 (ja) * | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US7244232B2 (en) * | 2001-03-07 | 2007-07-17 | Biomed Solutions, Llc | Process for identifying cancerous and/or metastatic cells of a living organism |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| MXPA05000403A (es) * | 2002-07-15 | 2005-07-22 | Genentech Inc | Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2. |
| US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| WO2005005636A1 (ja) | 2003-07-15 | 2005-01-20 | Chugai Seiyaku Kabushiki Kaisha | 形質転換細胞によるIｇMの産生とその定量方法 |
| KR101141507B1 (ko) * | 2003-07-21 | 2012-05-08 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. | 사람 상피 성장 인자 2/ｎｅｕ 항원을 암호화하는 합성 유전자 및 이를 포함하는 약제학적 조성물 |
| CN1993378A (zh) | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| CA2575830A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| WO2007073272A1 (en) * | 2005-12-23 | 2007-06-28 | Gcoder Systems Ab | Positioning pattern |
| CA2638907A1 (en) * | 2006-02-09 | 2007-08-23 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| NZ571692A (en) | 2006-05-05 | 2012-01-12 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
| US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
| CA2703585A1 (en) * | 2007-10-23 | 2009-04-30 | The Regents Of The University Of Colorado | Competitive inhibitors of invariant chain expression and/or ectopic clip binding |
| KR20110139292A (ko) | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
| KR20120089863A (ko) * | 2009-10-09 | 2012-08-14 | 사노피 | “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법 |
| CA2817250A1 (en) * | 2010-11-18 | 2012-05-24 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US9782452B2 (en) * | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| JP2016528295A (ja) | 2013-08-22 | 2016-09-15 | アクセルロン ファーマ， インコーポレイテッド | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| CN111700877A (zh) | 2014-09-03 | 2020-09-25 | 吉倪塞思公司 | 治疗性纳米粒子和相关的组合物、方法和系统 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| TWI856437B (zh) | 2017-01-20 | 2024-09-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| BR112019023071A2 (pt) | 2017-05-04 | 2020-06-09 | Acceleron Pharma Inc | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas |
| JP7526097B2 (ja) | 2018-03-06 | 2024-07-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 前立腺特異的膜抗原ｃａｒおよびその使用方法 |
| CN114814223A (zh) * | 2022-04-20 | 2022-07-29 | 昆明市妇幼保健院 | 一种用于监测及控制疟原虫治疗的系统及设备 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052A (en) * | 1845-05-13 | Tktjss | ||
| US20020004052A1 (en) * | 1990-05-08 | 2002-01-10 | David Berd | Composition comprising a tumor cell extract and method of using the composition |
| US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| US6197311B1 (en) * | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| CA2146973C (en) | 1992-10-29 | 2008-09-02 | Patricia R. Segarini | Uses of tgf-.beta. receptor fragment as a therapeutic agent |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5932212A (en) * | 1996-05-24 | 1999-08-03 | Altus Biologics, Inc. | Crosslinked protein crystal formulations and their use as catalysts in organic solvents |
-
1998
- 1998-09-16 ZA ZA988461A patent/ZA988461B/xx unknown
- 1998-09-16 MY MYPI98004237A patent/MY131805A/en unknown
- 1998-09-17 EP EP98949313A patent/EP1015031A4/en not_active Withdrawn
- 1998-09-17 KR KR1020007002864A patent/KR100540267B1/ko not_active Expired - Fee Related
- 1998-09-17 CA CA002303178A patent/CA2303178A1/en not_active Abandoned
- 1998-09-17 JP JP2000511527A patent/JP2001516727A/ja active Pending
- 1998-09-17 AU AU95658/98A patent/AU742216B2/en not_active Ceased
- 1998-09-17 CN CNB988112809A patent/CN1234413C/zh not_active Expired - Fee Related
- 1998-09-17 WO PCT/US1998/018495 patent/WO1999013912A1/en not_active Application Discontinuation
- 1998-09-17 IN IN2797DE1998 patent/IN190792B/en unknown
- 1998-09-17 RU RU2000109595/14A patent/RU2219947C2/ru not_active IP Right Cessation
- 1998-09-17 AR ARP980104649A patent/AR013012A1/es not_active Application Discontinuation
- 1998-09-17 IL IL13493798A patent/IL134937A0/xx not_active IP Right Cessation
- 1998-09-17 CO CO98053593A patent/CO4790100A1/es unknown
- 1998-11-04 SA SA98190719A patent/SA98190719B1/ar unknown
-
1999
- 1999-01-29 TW TW087115599A patent/TWI252108B/zh not_active IP Right Cessation
-
2000
- 2000-03-07 IL IL134937A patent/IL134937A/en unknown
- 2000-03-17 NO NO20001413A patent/NO20001413L/no not_active Application Discontinuation
-
2001
- 2001-05-14 US US09/853,580 patent/US20010018054A1/en not_active Abandoned
- 2001-05-14 US US09/853,581 patent/US6998125B2/en not_active Expired - Lifetime
-
2003
- 2003-12-24 US US10/743,739 patent/US20040137014A1/en not_active Abandoned
-
2005
- 2005-12-12 US US11/298,567 patent/US20060153848A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234413C (zh) | 2006-01-04 |
| AU9565898A (en) | 1999-04-05 |
| EP1015031A1 (en) | 2000-07-05 |
| US20040137014A1 (en) | 2004-07-15 |
| CN1279616A (zh) | 2001-01-10 |
| US20010018054A1 (en) | 2001-08-30 |
| HK1033653A1 (en) | 2001-09-14 |
| RU2219947C2 (ru) | 2003-12-27 |
| AR013012A1 (es) | 2000-11-22 |
| US20060153848A1 (en) | 2006-07-13 |
| IL134937A0 (en) | 2001-05-20 |
| TWI252108B (en) | 2006-04-01 |
| CO4790100A1 (es) | 1999-05-31 |
| ZA988461B (en) | 1999-03-30 |
| JP2001516727A (ja) | 2001-10-02 |
| EP1015031A4 (en) | 2004-03-17 |
| KR20010024109A (ko) | 2001-03-26 |
| US20010019715A1 (en) | 2001-09-06 |
| WO1999013912A1 (en) | 1999-03-25 |
| NO20001413D0 (no) | 2000-03-17 |
| KR100540267B1 (ko) | 2006-01-10 |
| NO20001413L (no) | 2000-05-18 |
| US6998125B2 (en) | 2006-02-14 |
| IL134937A (en) | 2008-04-13 |
| MY131805A (en) | 2007-09-28 |
| IN190792B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2003-08-23 |
| CA2303178A1 (en) | 1999-03-25 |
| SA98190719B1 (ar) | 2006-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU742216B2 (en) | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis | |
| US20230012022A1 (en) | Cancer vaccines and methods of treatment using the same | |
| AU765822B2 (en) | CD40 binding molecules and CTL peptides for treating tumors | |
| KR20160106082A (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
| JP2016537417A (ja) | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法 | |
| TW201938793A (zh) | 一種新型疫苗佐劑 | |
| JP2002538219A (ja) | 癌及び高増殖性疾患治療用の組成物及び方法 | |
| Zhang et al. | Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response | |
| US20080166369A1 (en) | Cancer Vaccine Preparation | |
| HK1033653B (en) | Synergistic composition and use thereof | |
| US8748390B2 (en) | Immunogenic epitopes of NGEP antigen | |
| US8367069B2 (en) | Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide | |
| KR20070019223A (ko) | 최적화된 유전자 코돈을 가지는 ｅ7 유전자 및 라이소좀타겟팅 시그널 서열을 포함하는 파필로마바이러스 유발질환의 예방 또는 치료용 조성물 | |
| JP2023533204A (ja) | 乳がんワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: BIOGEN IDEC INC. Free format text: FORMER NAME WAS: IDEC PHARMACEUTICALS CORPORATION |